Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC11A2 | P49281 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 9/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.35 |
| ▸ | MPO | P05164 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 5/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30320123 | 0.76 | PARP1 (0.46) | SLC11A2TAAR1ALOX5HMGB1MAPT | |
| SCHEMBL198085 | 0.76 | PARP1 (0.46) | SLC11A2TAAR1ALOX5HMGB1MAPT | |
| SCHEMBL8374054 | 0.75 | ALOX5 (0.55) | SLC11A2TAAR1ALOX5MPOHTR2A | |
| SCHEMBL198086 | 0.70 | SLC11A2 (0.40) | SLC11A2ALOX5HMGB1 | |
| SCHEMBL28843796 | 0.69 | KMT2A (0.41) | SLC11A2TAAR1ALOX5HMGB1HTR2A | |
| SCHEMBL23900879 | 0.69 | GLA (0.66) | TAAR1HTR2AMAPTSMN1; SMN2NPSR1 | |
| SCHEMBL143458 | 0.68 | MTNR1A (0.49) | CYP1A2CYP2D6MAPT | |
| SCHEMBL28607303 | 0.68 | ADH1B (0.36) | TAAR1MPOHTR2ACYP2D6CYP2A6 | |
| SCHEMBL6563339 | 0.68 | TAAR1 (0.54) | TAAR1HMGB1MPOSLC6A4HTR2A | |
| SCHEMBL11611663 | 0.67 | PNMT (0.41) | TAAR1HTR2ACYP2A6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107129538-B | Peptide conjugates of GLP-1 receptor agonists and gastrin and uses thereof | 西兰制药公司 | 2021-07-16 | — | — | CN | disclosed |
| US-10406207-B2 | Peptide conjugates of GLP-1 receptor agonists and gastrin and their use | ZEALAND PHARMA A/S (DK) | 2019-09-10 | — | — | US | disclosed |
| US-20170281709-A1 | PEPTIDE CONJUGATES OF GLP-1 RECEPTOR AGONISTS AND GASTRIN AND THEIR USE | ZEALAND PHARMA A/S (DK) | 2017-10-05 | — | — | US | disclosed |
| US-9649362-B2 | Peptide conjugates of GLP-1 receptor agonists and gastrin and their use | ZEALAND PHARMA A/S (DK) | 2017-05-16 | — | — | US | disclosed |
| EP-2563808-B1 | PEPTIDE CONJUGATES OF GLP-1 RECEPTOR AGONISTS AND GASTRIN AND THEIR USE | ZEALAND PHARMA AS (DK) | 2016-12-07 | — | — | EP | disclosed |
| US-20160184400-A1 | PEPTIDE CONJUGATES OF GLP-1 RECEPTOR AGONISTS AND GASTRIN AND THEIR USE | ZEALAND PHARMA A/S (DK) | 2016-06-30 | — | — | US | disclosed |
| US-9089538-B2 | Peptide conjugates of GLP-1 receptor agonists and gastrin and their use | ZEALAND PHARMA A/S (DK) | 2015-07-28 | — | — | US | disclosed |
| US-20130143793-A1 | PEPTIDE CONJUGATES OF GLP-1 RECEPTOR AGONISTS AND GASTRIN AND THEIR USE | ZEALAND PHARMA A/S (DK) | 2013-06-06 | — | — | US | disclosed |
| EP-2563808-A1 | PEPTIDE CONJUGATES OF GLP-1 RECEPTOR AGONISTS AND GASTRIN AND THEIR USE | Zealand Pharma A/S (DK) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011134471-A1 | PEPTIDE CONJUGATES OF GLP-1 RECEPTOR AGONISTS AND GASTRIN AND THEIR USE | ZEALAND PHARMA A/S (DK) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281709-A1 | PEPTIDE CONJUGATES OF GLP-1 RECEPTOR AGONISTS AND GASTRIN AND THEIR USE | GLP1R, GIPR, GRPR | SLC11A2 1937/4885TAAR1 768/4885ALOX5 4472/4885 |
| US-10406207-B2 | Peptide conjugates of GLP-1 receptor agonists and gastrin and their use | GLP1R, GIPR, GRPR | SLC11A2 1937/4885TAAR1 768/4885ALOX5 4472/4885 |
| US-20160184400-A1 | PEPTIDE CONJUGATES OF GLP-1 RECEPTOR AGONISTS AND GASTRIN AND THEIR USE | GLP1R, GIPR, GRPR | SLC11A2 1946/4885TAAR1 761/4885ALOX5 4470/4885 |
| US-20130143793-A1 | PEPTIDE CONJUGATES OF GLP-1 RECEPTOR AGONISTS AND GASTRIN AND THEIR USE | GLP1R, GIPR, GRPR | SLC11A2 1946/4885TAAR1 761/4885ALOX5 4470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.